Abstract
Prognosis of patients with renal carcinoma has improved since the advent of targeted therapies. These last years, due to the improvement of patients overall survival, the incidence of brain metastasis among renal carcinoma patients has increased. This worsens the prognosis of patients. The present revue aims to do a point on treatment of brain metastasis from renal carcinoma. It will address both locoregional (surgery, radiotherapy and stereotactic radiosurgery) and systemic (targeted therapies) treatments.
MeSH terms
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
Bevacizumab
-
Brain Neoplasms / mortality
-
Brain Neoplasms / secondary*
-
Brain Neoplasms / therapy*
-
Carcinoma, Renal Cell / mortality
-
Carcinoma, Renal Cell / secondary*
-
Carcinoma, Renal Cell / therapy*
-
Everolimus
-
Humans
-
Kidney Neoplasms*
-
Molecular Targeted Therapy / methods
-
Prognosis
-
Radiosurgery / methods
-
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
-
Sirolimus / analogs & derivatives
-
Sirolimus / therapeutic use
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Bevacizumab
-
temsirolimus
-
Everolimus
-
Receptor Protein-Tyrosine Kinases
-
Sirolimus